Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Phase I Trial With Expansion Cohort of OBP-301 (Telomelysin™) and Definitive Chemoradiation for Patients With Locally Advanced Esophageal and Gastroesophageal Cancer Who Are Not Candidates for Surgery

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT04391049
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:31.678650+00:00
Published At
2025-05-29T00:00:00+00:00
Record Updated At
2026-01-30
Results Posted At
2025-05-29
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Advanced Esophageal Adenocarcinoma", "Advanced Gastroesophageal Junction Adenocarcinoma", "Clinical Stage II Esophageal Adenocarcinoma AJCC v8", "Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage III Esophageal Adenocarcinoma AJCC v8", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage II Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage III Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage II Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Unresectable Gastroesophageal Junction Adenocarcinoma", "Squamous Cell Carcinoma", "Squamous Cell Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-01-30"
protocolSection.identificationModule.nctId
"NCT04391049"
protocolSection.identificationModule.officialTitle
"Phase I Trial With Expansion Cohort of OBP-301 (Telomelysin\u2122) and Definitive Chemoradiation for Patients With Locally Advanced Esophageal and Gastroesophageal Cancer Who Are Not Candidates for Surgery"
protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2025-05-29"

Study condition terms

  • Advanced Esophageal Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Advanced Gastroesophageal Junction Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Clinical Stage II Esophageal Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Clinical Stage III Esophageal Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Pathologic Stage II Esophageal Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Pathologic Stage III Esophageal Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Postneoadjuvant Therapy Stage II Esophageal Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Postneoadjuvant Therapy Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Unresectable Gastroesophageal Junction Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Squamous Cell Cancer (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.